* The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR)
* The report reviews Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
(21), (22) The amino acid L-arginine--and other amino acids used in combination--promote GHRH-stimulated GH release, (23) and amino acids have been used as secretagogues in several dietary supplements, but their effects may not be as potent or predictable as the use of a GHRP, such as GHRP-2.
The most recent innovations in the use of dietary supplements to stimulate GH secretion involve the use of GHRP, most notably GHRP-2.
(23) Furthermore, the administration of GHRP-2 in combination with GHRP or L-arginine can result in substantial increases in GH levels.
It is noted that GHRPs have greater GH-releasing actions than GHRP, and GHRP-2 can be administered by oral or intranasal routes with evidence of GH-releasing actions of a significant magnitude.
On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology.
GH responses to GHRP and to GHRH in GH deficient children.
GH secretion during continuous infusion of GHRP: partial response attenuation.
Role of selected endogenous peptides in GHRP activity: Analysis of GHRH, thyroid hormone-releasing hormone, and gonadotropin-releasing hormone.
Demonstration and characterization of the specific binding of GHRP to rat anterior pituitary and hypothalamic membranes.